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Abstract
NIH-PA Author Manuscript

The hPMS2 mutation E705K is associated with Turcot syndrome. To elucidate the pathogenesis of
hPMS2-E705K, we modeled this mutation in yeast and characterized its expression and effects on
mutation avoidance in mammalian cells. We found that while hPMS2-E705K (pms1-E738K in yeast)
did not significantly affect hPMS2 (Pms1p in yeast) stability or interaction with MLH1, it could not
complement the mutator phenotype in MMR-deficient mouse or yeast cells. Further-more, hPMS2E705K/pms1-E738K inhibited MMR in wild-type (WT) mammalian cell extracts or yeast cells only
when present in excess amounts relative to WT PMS2. Our results strongly suggest that hPMS2E705K is a recessive loss-of-function allele.
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1. Introduction
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DNA mismatch repair (MMR) is a highly conserved DNA repair pathway whose primary
function is to detect and repair mismatched DNA bases that spontaneously arise during DNA
replication and recombination. MMR also participates in the repair of other DNA lesions, acts
to suppress recombination between similar but not identical DNA sequences, and plays a role
in DNA damage surveillance. Extensive characterization of MMR in bacteria, yeast, and
mammals has led to the delineation of two groups of MMR proteins, the MutS and MutL
proteins. MutS proteins (e.g., MSH2, MSH6, and MSH3) recognize and bind mismatched or
damaged DNA base pairs, while MutL proteins (e.g., MLH1, PMS2, and MLH3) bind MutS
proteins and recruit additional proteins for excision of the mismatch and DNA resynthesis
(reviewed in [1–6]). In eukaryotes, the primary MutL and MutS complexes are composed of
PMS2 (Pms1 in yeast) and MLH1 (MutLα), and MSH2 and MSH6 (MutSα), respectively
(reviewed in [1–6]). Defects in the genes coding for these and other MMR proteins result in a
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mutator phenotype, characterized by higher rates of base pair substitutions and instability in
microsatellite sequences (MSI) (reviewed in [1–6]).
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The mutator phenotype was associated initially with hereditary nonpolyposis colorectal cancer
(HNPCC), a syndrome accounting for ~3% of colorectal cancers and predominantly caused
by mutations in MSH2 and MLH1. Until recently, the paucity of germline PMS2 mutations and
the absence of intestinal cancer in Pms2−/− mice [7,8] had been widely believed to indicate a
minimal role for PMS2 in the initiation of tumorigenesis, even though ample evidence
suggested that PMS2-deficiency results in a mutator phenotype [8–10]. However, recent
discoveries of new germline hPMS2 mutations have significantly reshaped views about the
relationship between PMS2 and cancer [reviewed in 11]. Based on their phenotypic effects,
germline hPMS2 defects can now be classified into two groups: (1) compound heterozygosity
or homozygosity for recessive PMS2 mutations is associated with Turcot syndrome and often,
café-au-lait spots and childhood onset of hematological cancers [12–16] and (2) heterozygosity
for a PMS2 mutation that is recessive at the cellular level, followed by mutation or loss of the
wild-type (WT) allele is associated with classic autosomal dominant inheritance of HNPCC
[17–19].
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Interestingly, one common feature of kindreds segregating the first group of PMS2 mutations
is that elevated MSI is observed in both tumor and non-neoplastic tissues of the patients, but
not in the transmitting parents or in heterozygous family members. The same phenomenon of
MSI in normal tissues was described in two reports of Turcot syndrome patients in whom only
one PMS2 mutation was originally detected: R134Ter [20] and E705K [21]. The patients
carrying hPMS2-R134Ter [20] were later found to carry a recessive mutation in the second
PMS2 allele [14]. This finding, coupled with the lack of MSI in the parents’ non-neoplastic
tissues and non-dominant functional effects in cultured human cells [22], suggested that
hPMS2-R134Ter is a recessive allele and not a dominant allele as originally proposed [23]. In
this report, we describe the characterization of hPMS2-E705K through yeast modeling,
expression in mouse cells, and in vitro MMR assays. We provide functional evidence that
hPMS2-E705K is a recessive allele and unlikely to be the sole etiologic factor for Turcot
syndrome in this family.

2. Materials and methods
2.1. Yeast strains, vectors, and fluctuation analyses
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S. cerevisiae strain W303 (ade2-1 leu2-3,112 his3-11,15c trp1-1 ura3-1 CAN1 RAD5
hom3-10; [24]) was used for gene targeting and over-expression studies. Growth conditions
for this strain and others generated in this study have been previously described [24], and
transformations were performed according to the polyethylene glycol–lithium acetate method
[25]. A 446 bp AatII/SphI fragment of pCoB-yPMS1-E738K (unpublished) was cloned into
AatII/SphI-digested pRS416-PMS1 [24], generating pRS416-pms1-E738K. To generate the 2
μ plasmids pRS426-PMS1 and pRS426-pms1-E738K, PvuII fragments of 4.4 kb from plasmids
pRS416-PMS1 and pRS416-pms1-E738K were cloned into PvuII-digested pRS426 [26]. The
targeting vector pRS406-pms1-E738K was constructed by cloning a 1.5 kb SpeI/SalI fragment
from pRS416-pms1-E738K into SpeI/SalI-digested pRS406 [26], and was then linearized with
HpaI for integration into the PMS1 genomic locus of W303 cells by a two-step allele
replacement method [27]. Construction of the W303 pms1Δ strain was explained previously
[24]. Mutations at hom3-10 and CAN1 loci in yeast were measured through fluctuation analyses
[28], and rates were determined as previously described [29]. The 95% confidence intervals
for mutation rates were calculated with PRISM 2.0a software (GraphPad Software, Inc.).
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2.2. Cultured cell lines
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The spontaneously-immortalized mouse embryonic fibroblast (MEF) cell lines used in this
study were: C18 [Pms2−/−; 30], CAKEM6.7 [WT; 31], MC5 [WT; 8], and MP1 [Mlh1−/−,
Pms2−/−; 32]. MEF cultures were grown as previously described [33].
2.3. Mammalian expression vectors
The construction of pCPB-hPMS2 has been described previously [33]. The Quikchange sitedirected mutagenesis kit (Stratagene) and mutagenesis primers hPMS2E705K.F 5′CAGCATGCCACGGACAAGAAGTATAACTTCG-3′ and hPMS2E705K.R 5′CGAAGTTATACTTCTTGTCCGTGGCATGCTG-3′ were used to introduce a G → A
mutation in codon 705 of a full-length hPMS2 cDNA cloned into pBluescript II. The desired
point mutation was verified through sequence analysis. EcoRI fragments of 2.7 kb in length
and containing either the full-length (including a 3′ UTR) WT or mutated hPMS2 cDNAs were
isolated and cloned into the EcoRI sites of pCPB to yield the plasmids pCPB-hPMS2 and
pCPB-E705K, respectively. The orientations of the cDNA inserts were determined through
restriction mapping, and the entire hPMS2 coding region was sequenced in each plasmid. The
construction of the pCNB-hMLH1 vector was described previously [34].
2.4. Transient transfections
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Plasmids bearing hMLH1 and hPMS2 cDNAs were transiently transfected into MP1 cells in a
manner similar to that described previously [33]. Briefly, various combinations and amounts
of purified (Endo-free Maxiprep, Qiagen) hMLH1, hPMS2, hPMS2-E705K, pCPB, and pCNB
DNAs were introduced into MP1 cells using Lipofectamine and Plus reagents (Invitrogen).
The empty vector DNA was used to equalize the mass of DNA transfected in each well of a
6-well plate to a total of 3 μg, and all reactions were performed in duplicate with two different
DNA preparations for each construct. Each experiment was repeated 3–4 times.
2.5. Generation of MEF clones stably expressing hPMS2
The C18 cell line was subcloned by limiting dilution, and metaphase spreads of 6 subclones
were prepared to identify subclones with diploid DNA content. The diploid subclone C18.2
was expanded and electroporated with 10 μg of pCPB, pCPBhPMS2, or pCPBE705K.
Following selection in puromycin for 7 days, 30 clones were expanded in duplicate 12-well
plates, and cells from one 12-well plate were subsequently lysed in 1X Laemmli sample buffer.
2.6. Analyses of hPMS2 expression
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Whole cell lysates of stably transfected C18.2 clones were electrophoresed on 8% SDS–PAGE
gels and transferred to Immobilon-P membrane (Millipore). Immunoblotting was performed
using anti-PMS2 monoclonal antibody A16-4 (1:500; BD Pharmingen) which detects both
human and mouse PMS2, and anti-MSH6 monoclonal antibody (1:2500 of clone 44; BD
Transduction Laboratories) which was used to control for equal loading of samples.
Chemiluminescent signals were developed with an enhanced chemiluminescence detection
system (Western Lightning, Perkin-Elmer Life Sciences) and captured on Kodak BioMax Light
film. The films were imaged on a UVP EC3 Bio-Chemi Imaging System (UVP Corp.), and
the absolute integrated optical density of individual protein bands was determined using the
Labworks 4.0 software package (UVP Corp.). To control for loading discrepancies, hPMS2
expression was normalized to endogenous mMSH6 expression.
Western analysis of hPMS2 expression in transiently-transfected MP1 cells was performed
essentially as described previously [33]. Proteins were detected with primary monoclonal
antibodies against hMLH1 (1:200 of clone G168-728; BD Pharmingen), hPMS2 (1:500 of
clone A16-4; BD Pharmingen), and α-tubulin (1:1000 of clone B 5-1-2; Sigma). Following
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incubation with a 1:5000 dilution of a horseradish peroxidase-coupled goat anti-mouse
antibody (Jackson Immunoresearch), ECL Plus Western Blotting Detection Reagents
(Amersham) were used to visualize proteins. Chemiluminescent signals were captured with
the UVP EC3 BioChemi Imaging System (UVP Corp.), and densitometry was performed as
described earlier. PMS2 band densities were divided by the band densities for endogenous
mouse α-tubulin in each lane to correct for loading discrepancies.
2.7. MSI analyses
Non-isotopic detection of the frequency of MSI at 5–6 of the mouse dinucleotide repeat loci
D4Mit27, D19Mit41, D13Mit67, D16Mit4, D17Mit123, and D13Mit139 was performed in up
to 12 subclones of each cell line, exactly as described previously [35].
2.8. In vitro MMR assays

NIH-PA Author Manuscript

The construction of baculovirus expression vectors (pFastBac Dual; Invitrogen) containing
full-length hMLH1 and 6× His tagged-hPMS2 cDNAs was described previously [32]. To
generate a pDUAL-hPMS2-E705K construct, a 1.6 kb PvuII-AatII fragment of the hPMS2E705K cDNA was cloned into the PvuII-AatII sites of the pDUAL-hPMS2 vector and verified
through restriction analysis and sequencing of the complete coding region. Recombinant
hMutLα was produced in Spodoptera frugiperda (Sf9) insect cells using the Bac-to-Bac
Baculovirus Expression system (Invitrogen), and purified by nickel affinity and ion exchange
chromatography as described previously [32]. The purified proteins were electrophoresed on
8% SDS–PAGE gels, visualized with Coomassie blue stain, and relative amounts were
determined with Quantity One software (BioRad).
MP1 and MC2 cell lines were expanded in up to forty 150 mm plates and harvested, and
cytoplasmic extracts were prepared as described [36]. The HeLa nuclear extract was a kind
gift from Dr. Paul Modrich (Duke Univ. Medical Center, Durham, NC). Circular, doublestranded DNA substrates containing a 5′ nick and either a G/T mismatch or a 1 bp insertion/
deletion loop (IDL) were prepared as described earlier [32] and used for in vitro MMR assays
with the relevant cytoplasmic or nuclear extracts. The percent repair efficiency represents the
sum of the intensity (as determined with Quantity One software, BioRad) of repaired DNA
substrates divided by the sum of the intensity of repaired and unrepaired DNA substrates.

3. Results
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The glutamic acid residue at codon 705 of hPMS2 lies within a highly conserved region of the
MLH1-interacting domain of Pms1p in yeast and PMS2 in mice and humans (Fig. 1),
suggesting an important functional role for this residue. To elucidate the effects of the
E705K allele on MMR-mediated mutation avoidance, we used both in vivo and in vitro
methodologies.
3.1. Analyses of mutation rates in yeast expressing pms1-E738K
To determine the effect of the homologous PMS2 mutation pms1-E738K on MMR function in
yeast, rates of reversion of a +1 T insertion at the hom3-10 locus [37] were measured in the
W303 strain background. Cells with a genomic pms1-E738K mutation expressed as much
Pms1p as WT cells (data not shown), and exhibited a mutation rate at the hom3-10 locus
comparable to that of a pms1δ strain (Table 1). Thus, the E738K mutation inactivates MMR
but does not appear to affect Pms1p stability in yeast. To determine whether pms1-E738K can
exert a dominant effect on MMR, WT W303 yeast cells were transformed with either CEN
(generally single-copy) or 2 μ (high-copy) plasmids bearing pms1-E738K, and reverse and
forward mutation rates were measured at hom3-10 and CAN1 (reports a wide mutational
spectrum) loci, respectively. In yeast expressing pms1-E738K from a CEN plasmid, mutation
Cancer Lett. Author manuscript; available in PMC 2008 May 5.
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rates were low and comparable to that of WT cells expressing either empty plasmid or
PMS1. In contrast, cells expressing pms1-E738K from a 2 μ plasmid exhibited increased
mutation rates relative to PMS1 expressors (Table 1). As pms1-E738K exerts dominant effects
on MMR in WT cells only when over-expressed, it behaves as a recessive, loss-of-function
allele in yeast.
3.2. Expression and functional analyses of WT and mutant hPMS2 in MMR-deficient MEFs
To evaluate the expression of hPMS2-E705K in mammalian cells, we used a transient
transfection assay that allows rapid assessments of MLH1 and PMS2 stability [33]. As shown
in Fig. 2A, hPMS2 and hPMS2-E705K were expressed at nearly equivalent levels in
hMutLα-deficient MP1 cells in the presence of hMLH1, which is known to stabilize hPMS2
through direct interaction [33]. To specifically determine whether hPMS2-E705K was less
stable than its wild-type counterpart, MP1 cells were transiently-transfected with 0.25–2 μg of
hPMS2 or hPMS2-E705K cDNA alone (Fig. 2B). Quantitation of the PMS2 signals on
immunoblots revealed that there was no significant difference in stability between WT and
mutant hPMS2 in these cells (Fig. 2C).
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Next, we tested the ability of hPMS2-E705K to complement the mutator phenotype of
Pms2−/− MEFs (C18 cells). It was expected that hPMS2 would heterodimerize with mMLH1
in MEFs to yield functional MutLα complexes because human and mouse PMS2 are highly
conserved and functional transspecies MutLα have been reported previously [34,38]. The
mutator phenotypes of a vector-transfected clone and two clones expressing nearly equivalent
amounts of WT hPMS2 or hPMS2-E705K (Fig. 3) were analyzed by determining the mutation
frequency at 5–6 microsatellite loci. While mutation levels were very low in the WT hPMS2transfected clone, the microsatellite mutation frequencies in vector and hPMS2-E705Ktransfected cells were comparably elevated (Table 2), indicating that hPMS2-E705K cannot
complement the mutator phenotype of C18 cells, even when expressed at levels comparable
to WT hPMS2.
3.3. Characterization of MMR in MP1 cytoplasmic extracts supplemented with hMutLα-E705K
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Our earlier studies had shown that WT but not mutant recombinant hMutLα can complement
cytoplasmic extracts of MP1 cells [32]. A similar strategy was used to characterize the mutation
avoidance activity of hPMS2-E705K relative to WT PMS2. As shown in Fig. 4A, the amount
of hPMS2-E705K is similar to that in both WT hMutLα and a non-functional mutant form of
hMutLα (hMutLα-mE34A/pE41A, [32]) with mutations affecting the ATPase activities of both
hMLH1 and hPMS2. Thus E705K has little, if any, effects on hPMS2 stability. Furthermore,
the stoichiometry of MLH1 to PMS2 was comparable in WT and mutant hMutLα complexes,
indicating that the mutation has minimal effects on heterodimerization of hMLH1 and hPMS2
in insect cells. Consistent with this conclusion, yeast two-hybrid analysis revealed that
Mlh1p:Pms1p-E738K interaction was not significantly reduced relative to WT Mlh1p:Pms1p
interaction (data not shown). Taken together, these data suggest that residue 705/738 has
minimal effects on hPMS2/Pms1p stability or heterodimerization with hMLH1/Mlh1p.
Next, either hMutLα or hMutLα-E705K was added to cytoplasmic extracts of the MutLαdeficient MEF cell lines MC2 and MP1. MC2 cells are MutLα-deficent because in the absence
of MLH1, PMS2 is unstable [e.g., 34]. Whereas hMutLα exhibited efficient 5′ nick-directed
repair of a 1 bp IDL, hMutLα-E705K showed little to no activity in repairing the same
mismatch, even when present at twice the amount of hMutLα in MC2 extract (Fig. 4B). The
same mismatch correction defect was observed in HCT116 (human colorectal carcinoma cells
deficient in MLH1) cytoplasmic extracts supplemented with hMutLα-E705K versus hMutLα
(data not shown).
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To determine if hPMS2-E705K can dominantly inhibit mammalian MMR, purified hMutLαE705K was added to a HeLa nuclear extract and in vitro MMR assays were performed. In this
extract endogenous hMutLα is not limiting, as it contains ~100 ng (560 fmol) of endogenous
hMutLα, which is twice that required for maximal activity in reconstituted in vitro MMR
reactions [39]. Thus, we reasoned that only the addition of excess hMutLα (e.g., 200 ng and
400 ng) would be likely to provoke changes in MMR activity. As shown in Fig. 4C, the repair
of a 5′ nicked substrate with a G/T mismatch was inhibited by up to 50% when hMutLα-E705K
was added. Addition of equivalent amounts of WT hMutLα or hMutLαmE34A/pE41A did not
negatively affect MMR in the same extract, excluding the possibility of artifact-induced MMR
inhibition (Fig. 4C). Furthermore, the failure of hMutLα-mE34A/pE41A to dominantly inhibit
MMR indicates that the mere presence of a non-functional mutant hMutLα complex is not
sufficient to explain the negative effects exhibited by hMutLα-E705K. These results are
interesting in light of a recent report in which hMutLα was shown to lose single-stranded
endonucleolytic activity as a result of either the E705K or mE34A/pE41A substitutions [40].
Finally, the inhibitory effects of excess hMutLα-E705K were also observed for the 5′ nickdirected repair of a 1 bp IDL in HeLa nuclear extract and when defined ratios of purified WT
hMutLα and hMutLα-E705K were added to MMR-deficient cytoplasmic extracts (data not
shown). Consistent with the results of the yeast mutator assays, then, the in vitro MMR data
demonstrate that hPMS2-E705K exerted dominant effects on MMR only when present in
excess over WT hPMS2.

NIH-PA Author Manuscript

4. Discussion
In this report, we describe the use of three different model systems to characterize the
expression and mutation avoidance function of hPMS2-E705K, an allele found in a Turcot
syndrome patient [21]. When introduced into yeast, insect, and mouse cells, this mutant Pms1p/
hPMS2 was expressed at or near-equivalent levels to its WT counterpart and appeared to
heterodimerize with MLH1 with an efficiency comparable to that of WT Pms1p/hPMS2. We
demonstrated that the orthologous mutation, pms1-E738K, inactivated the mutation avoidance
function of MMR in yeast. Similarly, hPMS2-E705K did not complement the mutator
phenotype of Pms2-deficient MEFs. In vivo, Pms2−/− MEFs transfected with hPMS2-E705K
exhibited high microsatellite instability, and in vitro purified hMutLα-E705K failed to restore
MMR activity in MMR-deficient MEF cytoplasmic extracts. Finally, we found that (1) pms1E738K exerted dominant effects on MMR in WT yeast only when it was over-expressed, and
(2) purified hMutLα-E705K could inhibit MMR-proficient HeLa nuclear extracts only when
added in excessive amounts. Taken together, our results strongly suggest that hPMS2-E705K
is a recessive loss-of-function allele rather than a dominant allele.
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Assuming that hPMS2-E705K is a recessive allele, two alternative explanations for the
pathogenesis of Turcot syndrome in the E705K patient [21] can be made. First, a second and
possibly different PMS2 mutation in the patient may have escaped detection because of the
confounding effect of paralogous genes on PMS2 mutation identification [e.g., 14,17] and thus
could account for the presence of the phenotype in the E705K patient but not the parents.
Indeed, the use of sequencing techniques designed to circumvent PMS2 pseudogene sequences
has led to the identification of compound heterozygosity or homozygosity for recessive
PMS2 mutations in families with no history of colorectal cancer and probands with café-aulait spots and hematological or brain cancers:, 1221delG/2361delCTTC [12],
1169ins20/1169ins20 [13], R134Ter/2184delTC [14], R802Ter/R802Ter [14,16], and
Y181Ter/Y181Ter [16]. These findings, coupled with recent reports of heterozygosity for
recessive PMS2 mutations associated with autosomal dominant inheritance of HNPCC [17–
19], suggest that the population frequency of recessive PMS2 mutations may be as high as the
MSH2 mutant allele frequency, albeit with lower penetrance [18].
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Second, the E705K patient may have carried a second recessive, but undetected, mutation in
another MMR or DNA repair gene, or in a gene involved in assuring DNA replication fidelity.
Heterozygosity for recessive mutations in two different mutation avoidance genes could result
in a mutator phenotype through either synergistic effects on mutation rates [41] or “unlinked
non-complementation” [42].
Until recently, the significance of the evolutionary conservation of residue 705 and surrounding
residues was unknown. After the completion of our studies, Kadyrov and colleagues reported
that residue 705 of hPMS2 is critical for a latent, single-stranded endonucleolytic activity in
hMutLα that is stimulated in in vitro reconstituted MMR reactions [40]. The introduction of
the E705K substitution in hPMS2 inactivated the endonucleolytic activity of hMutLα,
suggesting that residue 705 is part of a highly conserved amino acid motif in the active site of
the latent endonuclease. The same single-stranded endonucleolytic activity has also been
observed in yeast MutLα. In this report we extend the above findings by demonstrating that
residue 705/738 is critical in vivo for the mutation avoidance function of human PMS2 and
yeast Pms1p. Thus, the hPMS2-E705K-associated inactivation of endonucleolytic activity in
hMutLα [40] likely explains the loss-of-function phenotype that we observed in both
mammalian and yeast cells.
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Fig. 1.
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Conservation of residue E705 in PMS2 homologs. The non-conservative E → K substitution
occurs in hPMS2 residue 705, which is located in a highly conserved region of the MLH1
interaction domain.
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Fig. 2.
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Expression of hPMS2-E705K in transiently transfected mouse cells. (A) Representative
immunoblot of whole cell lysates (WCLs) of MP1 cells transfected with hMLH1 (1 μg).
hPMS2 (0.25 μg,), and/or hPMS2-E705K (0.25 μg) cDNAs, together with pCPB (1.25–1.5
μg) and pCNB (0.5–1.5 μg) empty vector DNAs to bring the total amount of DNA transfected
to 3 μg. (B) Representative immunoblot of WCLs of MP1 cells transfected with 0.25–2 μg of
hPMS2 or hPMS2-E705K cDNAs. (C) Quantitative analysis of PMS2 expression in MP1 cells
transfected with increasing amounts of hPMS2 versus hPMS2-E705K cDNAs. Each point on
the graph represents the average of 3–4 experiments consisting of duplicate transfections.
Linear regression was performed on each data series.
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Fig. 3.
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Expression of hPMS2 and hPMS2-E705K in stably transfected mouse cells. Whole cell lysates
prepared from a subset of C18.2 clones expressing nearly equivalent amounts of hPMS2 and
hPMS2-E705K were electrophoresed, immunoblotted, and quantitated via densitometry as
described in Section 2. All PMS2 signals were normalized to endogenous mMSH6 expression
in each lane, and relative amounts of PMS2 were calculated by dividing all PMS2 signals by
the signal detected in clone hPMS2-16 (lane 2).
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Fig. 4.

In vitro analyses of the ability of hMutLα-E705K to complement MMR deficiency or
dominantly inhibit MMR.(A) Coomassie-stained SDS–PAGE gel containing recombinant
wild-type and mutant hMutLα that was purified from baculovirus-transduced insect cells
through nickel affinity and ion exchange chromatography. hMutLα-mE34A/pE41A, a nonfunctional hMutLα complex with wild-type MLH1/PMS2 stoichiometry [31], was included
for comparison purposes. (B) The 5′ nick-directed repair of a 1 bp IDL was determined in
cytoplasmic extracts of MutLa-deficient MEFs supplemented as follows: 350 ng of wild-type
or 700 ng of mutant MutLα was added to MC2 extract, whereas 100 ng of either complex was
added to MP1 extract. (C) To a HeLa nuclear extract, 200–400 ng of wild-type or mutant
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hMutLα was added and its ability to perform 5′ nick-directed repair of a G/T mismatch was
determined through agarose gel electrophoresis and densitometry.
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1.4
873
971

Mutation rate
(×10−8)

hom3-10

95% confidence intervals are indicated in parentheses.

b

In WT W303 yeast cells.

a

PMS1
pms1Δ
pms1-E738K

Genotype (genome)

1
642
714

Fold increase

Empty vector
PMS1 (CEN)
pms1-738 (CEN)
PMS1 (2 μ)
pms1-738 (2 μ)

Genotype(plasmid)a

0.9 (0.7–1.1)
1.1 (0.6–1.6)
1.7 (0.9–2.5)
3.3 (1.4–5.2)
213 (165–262)

Mutation rate
(×10−8)a,b

hom3-10

1
1.2
1.9
3.7
237

Fold increase

24 (11–37)
30 (23–37)
36 (18–53)
27 (23–30)
184 (54–314)

Mutation rate
(×10−8)a,b

CAN1

1
1.3
1.5
1.1
7.7

Fold increase
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Table 2

Frequency of MSI in Pms2-deficient MEFs stably transfected with hPMS2 or hPMS2-E705K
Cell line

MSI frequency (%)
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Vector
hPMS2-31
E705K-5

13.3
4.6
18.3
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